Publications

The First-in-Class Anti-Staphylococcal Antibiotic Afabicin Desphosphono is Not Associated With Clostridioides difficile Infection in an in vitro Human Gut Model

Assessment of Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment for the Anti-Staphylococcal Antibiotic Afabicin

Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal…

Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors

Debio 0123 + Carboplatin for Patients with Advanced Solid Tumors: Safety, Preliminary Efficacy and Determination of Recommended Phase 2 Dose

Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin and etoposide in patients with small cell lung cancer that…

Theranostic targeting of CAIX in patients with clear cell renal cell carcinoma: first‑in‑human safety, imaging and dosimetry findings with [68Ga]Ga‑DPI-4452

Population PK and Exposure-Response Modeling to Support the Design of Trials with DEBIO 0123, a WEE1 Inhibitor, in Cancer Patients

CD37 is a Relevant Target for AML and MDS Treatment with Debio 1562M Antibody Drug Conjugate (ADC)